New radioactive antibody could light up Hard-to-Treat cancers
NCT ID NCT07272642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scans. The main goal is to check safety and how the agent spreads in the body, not to treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTH-2403 (a radiolabeled antibody that binds to a protein on cancer cells and nearby cells, used for imaging)
What this could lead to
If successful, this could improve how doctors see and locate certain advanced solid tumors, and may pave the way for targeted treatment.
What could go wrong
This is a very early, small study (16 people) focused on safety and imaging, not treatment. It may not lead to effective therapy, and radiation exposure carries risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Centre Hollywood
Nedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••